MELISSA BELANGER: Open Payments
NPI 1396046561 · NORMAN, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,286 in 88 payments from 9 companies in 2025. Trend: 2023 $1,912 · 2024 $2,021 · 2025 $1,286
Food & beverage: $1,286
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 15 | $274 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $265 |
| Vanda Pharmaceuticals Inc. | 17 | $236 |
| Janssen Pharmaceuticals, Inc | 15 | $165 |
| Supernus Pharmaceuticals, Inc. | 8 | $147 |
| Axsome Therapeutics, Inc. | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 3 | $58 |
| E.R. Squibb & Sons, L.L.C. | 3 | $46 |
| IDORSIA PHARMACEUTICALS US INC | 2 | $36 |
Products named: CAPLYTA, FANAPT, REXULTI, Qelbree, SPRAVATO, NUEDEXTA, Auvelity, INVEGA SUSTENNA.
Industry payments across OK — which companies pay providers there.
